Bausch + Lomb Drops $1.75B for Novartis’ Dry Eye Treatment

The acquisition, valued at up to $2.5 billion, marks the first major move by Bausch + Lomb CEO Brent Saunders since he took the company’s helm in March.

Scroll to Top